neuroClues

🔥 We are so excited to share with you that NeuroClues™ is amongst the very few promising start-ups (<8%) awarded the prestigious EIC accelerator funding! We are now ready to move to the next phase: demonstrating the clinical use of neuroClues in the diagnosis of Parkinson’s Disease and supporting its early commercial roll-out!   🇪🇺 The European Innovation Council (EIC) is the EU Commission's flagship innovation program to identify, develop and scale up breakthrough technologies and game-changing innovations. The EIC Accelerator provides substantial financial support with grant funding and direct equity investments managed by the EIC Fund. 🚀 This recognition confirms our ambition for NeuroClues™ to become the brain’s stethoscope, supporting 10M patients by 2030. Congratulations to the whole team! We’re on the right track to fulfill our mission, with the support from Institut du Cerveau – Paris Brain Institute and iPEPS The Healthtech Hub. More info on the press release: https://lnkd.in/g5pZPmAH European Innovation Council and SMEs Executive Agency (EISMEA) invest.bw Graph Ventures Pierre de Waha L'Echo Antoine Pouppez Pierre Daye Pierre Pouget Jean-Baptiste de Harenne Marie Dautrebande Camille Verriest Frédérique Boël Florian Guyot Mark Turcksin Alejandra Mejia Philippe Domineaux Valérie Roels Caroline Van den Eynde @Tym Poitou Bao Nguyen Simon Gerard   #EUeic #eicAccelerator #neuroscience #innovationinhealthcare #capitalventure #funding #scaling

Each person living with Parkinson’s disease (PD) will have a unique journey with their treatments, including the decision to have deep brain stimulation (DBS), which is a surgical procedure to treat Parkinson’s motor symptoms. While DBS isn’t suitable for everyone, it can be helpful in the right person, and it’s a complex, lifelong choice. In our newest podcast episode, you’ll hear from our expert panel: • Larry Gifford, co-founder of PD Avengers and MJFF Patient Council member who had DBS surgery in 2023 • Becca Miller, PhD, licensed clinical psychologist, associate professor at Yale School of Medicine and MJFF Patient Council member who had DBS surgery in 2021 • Pavan Vaswani, MD, movement disorder specialist and assistant professor of clinical neurology at Penn Medicine, University of Pennsylvania Health System • Ajmal Zemmar, MD, practicing neurosurgeon and assistant professor of neurosurgery at the University of Louisville School of Medicine Together, they tackle community-sourced questions on DBS surgery day: what to wear, how loved ones can support, what it feels like to be awake during brain surgery and more. Listen to the episode: https://bit.ly/48Ktxpz

Slowly but surely, the European Union 🇪🇺 recognises that brain 🧠 health is one of, if not the most important aspects of medicine and wellbeing in the 21st century! Exciting opportunity to discuss the future of brain health research in Europe. Brain Health = Mental Health #savethebrain

⚡️ This week was extra special at neuroClues – we had our last team-building event before 2025! 🤝  As a company with flexible work-from-home policies and employees based in different countries, we love to gather a few 3 times a year to connect in person. And we love it! 🌍 This time, we had the pleasure of showing our French colleagues around the beautiful city of #Brussels with Coddy Games. We enjoyed a scenic walk, taking on fun challenges along the way, and of course, soaking in the local culture. 🌱 Sustainability is a topic we care about deeply at neuroClues, and we were thrilled to have @Emma Krug from Oxfam lead a session on the challenges of climate change, with a special focus on the scientific aspects. We know our responsibility as a MedTech company, and we’re committed to actively working towards a more sustainable future. 🍫 And what’s a visit to Brussels without chocolates? We wrapped up the teambuilding days with a delicious experience at the Belgian Chocolate Workshop, where we learned to make our own pralines! Safe to say, we left with full stomachs and maybe a little chocolate-induced belly ache... ✨ At neuroClues, team spirit is everything. It’s the foundation of our culture – working together, supporting one another, and celebrating both big and small moments as a team. Here’s to many more adventures and collaborations in the future! Thanks team and a special thanks to Emilie Boucquey for organizing these amazing days💙 Pierre Daye Antoine Pouppez Pierre Pouget Jean-Baptiste de Harenne Frédérique Boël Philippe Domineaux Simon Gerard Marie Dautrebande Valérie Roels Marie Coulon Florian Guyot Camille Verriest Bao Nguyen Alejandra Mejia Valentin Van Cauwenberg Gaëtan Vanhoutte Shivani Venkatram Thibaud D. Céline Kayal, PhD Komivi Gédéon A. Ioan-Charly 't Kint @Matthieu Jacquemin @Tymothée Poitou Shirine Molaynejad

🔍 Did you know that eye movements can be instrumental in diagnosing diseases and guiding pharmaceutical research for new medications? They can reveal crucial information about damage at neurotransmitter and their location! 📩In our November newsletter, we highlight how integrating eye movement analysis into pharmaceutical research can open new possibilities and enhance studies on treatments for neurological diseases. Here’s how eye movements could play a pivotal role: ⚡️Stratifying Patient Populations: Selecting the right participants for your study is critical. For instance, distinguishing between idiopathic #Parkinson's Disease and similar conditions like #PSP, #MSA, or #CBS can be challenging. Patients end up in MSA trials to find out they have a different condition. On top of bringing false hopes to patients, this degrades study performance. Eye movements could help clarify diagnoses, ensuring the appropriate patients are recruited. ⚡️Monitoring Treatment Progression: Assessing how treatments evolve over time is essential. And particularly complex with clinical scales in slowly-evolving diseases: degradation over time may be too subtle for the scales. An objective, quantifiable tool for monitoring outcomes is necessary, and eye movement analysis could provide that precision. ⚡️Predicting a Prognosis: Prognostic predictions play a crucial role in managing neurological diseases, allowing for earlier interventions and tailored treatment strategies.  👀Eye movements are controlled by different areas of the brain. When we observe abnormalities in these movements, we could identify the specific brain region affected and the nature of the damage. Additionally, injuries to neurotransmitter systems can lead to distinct eye movement patterns, which can serve as valuable biomarkers for neurological conditions, and provide insights into the working of the studied molecules. ❓Want to learn more about how eye movements enhance clinical trials and improve access to better treatments for neurological diseases? Check out our full newsletter! * neuroClues is in research & development phase and its commercial availability is pending regulatory approval. #biomarkers #neuroscience #eyetracking

👀 Les mouvements des yeux: une aide au diagnostic différentiel des syndromes parkinsoniens atypiques?  Nous vous présentons notre projet en développement lors de la réunion de la #Sofma24 à Strasbourg aujourd’hui ! ⚡️La Société Francophone des Mouvements Anormaux (SOFMA) regroupe les spécialistes des troubles du mouvement. Elle fédère les acteurs du domaine, partage des informations pertinentes et soutient la recherche, tout en offrant une plateforme de collaboration pour les experts neurologiques. 🧠 Les mouvements anormaux regroupent plusieurs troubles neurologiques caractérisés par des mouvements involontaires. Parmi les plus connus, les syndromes parkinsoniens, tels que la maladie de Parkinson (#PD), mais aussi ses syndromes atypiques tels que la paralysie supranucléaire progressive (#PSP), la dégénérescence corticobasale (#DCB) et l’atrophie multi-systématisée (#AMS), sont particulièrement importants à souligner en raison des difficultés qu'ils posent en matière de diagnostic en raison de leurs nombreuses similitudes. 🩺 Un diagnostic précis de ces maladies est primordial pour garantir une prise en charge appropriée des patients, leur administrer les traitements adaptés, qui varient en fonction de la maladie, et pour pouvoir anticiper la progression de la pathologie. 🔍 L'analyse des mouvements des yeux pourrait être la solution à ce problème. Les syndromes parkinsoniens atypiques peuvent être distingués grâce à des schémas d'anomalies spécifiques des mouvements oculaires. C'est pourquoi un outil précis, objectif et facile à utiliser en consultation, capable d'analyser ces mouvements, pourrait devenir un précieux allié pour le neurologue dans son diagnostic. 💥Venez découvrir à notre stand comment l’analyse des mouvements des yeux peut devenir l’allié précieux d'une consultation neurologique. #biomarkers #neuroscience #eyetracking #Sofma24 * neuroClues est en phase de recherche et développement et sa commercialisation est soumise à l'approbation des autorités réglementaires.

🚀 Exciting times ahead as we gear up for Ghent Slush'D, the largest gathering of founders and investors in Belgium! 🇧🇪This incredible event will bring together innovators from Flanders, Brussels, and Wallonia to share insights, connect with over 150+ investors, and help put Belgian startups on the global stage. 🌍 🤝At neuroClues, we’re excited to be part of this journey alongside Wallonia Export & Investment Agency, whose support helps Wallonian startups like ours expand and thrive. Collaboration drives our success, and we’re looking forward to achieve great things together. ❓What we do:  The eyes are a window to the brain, offering valuable insights into neurological health.  neuroClues aims to provide neurologists with objective, quantifiable data, integrating the wealth of eye-tracking directly into their consultation. In other words, we aim to become the brain’s stethoscope.  👀Curious to learn more? Connect with our CEO - Antoine Pouppez, and discover how eye movements can transform neurological diagnosis. See you in beautiful Ghent! #Biomarkers #neuroscience #eyetracking #ghentslushd #industryleaders #GhentSlushD #startup * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.  

👀"The eyes might just be the most underrated superheroes we have," said Anca Petre, host of the Science for Care podcast. 🎙️In the latest episode, co-founders Pierre Pouget and Antoine Pouppez discuss the critical role of eye tracking in neurology and how neuroClues could bring innovation to the field. 🥼 Today, neurologists rely on clinical observation during consultations to assess patients, but they often lack quantitative data within the short time frame of a 20-minute consultation. neuroClues seeks to offer objective measurements to complement these observations, aiming to add value to neurologists’ existing expertise, all without extending the consultation time or avoiding complementary exams. 🎧 Listen to the podcast and learn more about the fascinating perspectives opened by the clinical use of eye tracking! ⚡️ If you're interested in learning how this technology could further support neurological diagnosis, please reach out. We'd love to share more insights! HealthTech For Care #biomarkers #neuroscience #eyetracking  #neurology * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

📢 Exciting insights from Marie VIDAILHET's recent review on the often-overlooked visual impairments in Parkinson's Disease (PD) and their potential as biomarkers for early diagnosis and disease progression! Key findings: 🔑Saccades and anti-saccades are examined as potential biomarkers for assessing motor and cognitive burdens in #PD. Abnormalities in these eye movements correlate with disease severity and can predict future complications such as freezing of gait. 🔑Eye movement analysis can aid in distinguishing between PD and other parkinsonian syndromes like Progressive Supranuclear Palsy (#PSP) and Multiple System Atrophy (#MSA).  🔑Convergence insufficiency (CI) is prevalent in PD patients, affecting their ability to focus on near objects and leading to difficulties in tasks like reading 🔑Optical coherence tomography (OCT) is highlighted as a valuable tool for detecting early structural changes in the retina, serving as a potential early diagnostic marker for PD. ⚡️The review emphasizes integrating eye movement analysis into clinical practice to improve diagnostic accuracy and monitor disease progression. Ocular assessments provide valuable insights into PD that extend beyond traditional motor symptoms. #biomarkers #neuroscience #eyetracking

📣We are thrilled to announce that neuroClues is one of the 10 finalists in the Health Tech Challengers, under the Disruptive Diagnosis track! 🌐 Health Tech Challengers is a prestigious platform for digital health startups, giving them the opportunity to showcase how they are shaping the future of healthcare. Out of 10 finalists in each of the 8 digital health tracks, one winner will be chosen based on their pitch, and we are honored to stand alongside such innovative companies. 💥 How is neuroClues disruptive?  Eye movements are the window into the brain. Long before clinical symptoms appear, eye movements can offer clues about neurological health. By providing an objective, quantifiable, and quick way to measure ocular biomarkers, neuroClues could empower clinicians to make more accurate diagnoses—potentially reducing the need for costly and time-consuming tests. 🎯 In essence, we aim to be the stethoscope for the brain. 🙌 A big thank you to Health Tech Challengers and the panel of experts for this recognition. Congratulations to all the other finalists—we’re excited to hear your pitches and learn how your innovations are transforming healthcare! 🚀 And of course, Antoine Pouppez, we can't wait to see you pitch at Health Tech Forward in December, you've got this! #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.